Geode Capital Management
VTGN icon

Geode Capital Management’s VistaGen Therapeutics VTGN Stock Holding History

Geode Capital Management’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$259K Buy
453,391
+100,555
+28% +$61.1K ﹤0.01% 3838
2025
Q4 		$234K Buy
352,836
+54,556
+18% +$197K ﹤0.01% 3854
2025
Q3 		$1.06M Buy
298,280
+25,373
+9% +$75.8K ﹤0.01% 3365
2025
Q2 		$546K Buy
272,907
+2,720
+1% +$6.18K ﹤0.01% 3528
2025
Q1 		$676K Buy
270,187
+13,261
+5% +$37.5K ﹤0.01% 3435
2024
Q4 		$758K Sell
256,926
-1,598
-0.6% -$4.5K ﹤0.01% 3462
2024
Q3 		$778K Sell
258,524
-31,570
-11% -$108K ﹤0.01% 3441
2024
Q2 		$1.01M Buy
290,094
+10,612
+4% +$46K ﹤0.01% 3302
2024
Q1 		$1.48M Buy
279,482
+5,010
+2% +$24.1K ﹤0.01% 3228
2023
Q4 		$1.41M Buy
274,472
+201,308
+275% +$762K ﹤0.01% 3214
2023
Q3 		$384K Buy
73,164
+15,842
+28% +$70.3K ﹤0.01% 3701
2023
Q2 		$107K Sell
57,322
-57,672
-50% -$202K ﹤0.01% 4309
2023
Q1 		$430K Buy
114,994
+5,907
+5% +$31K ﹤0.01% 3700
2022
Q4 		$337K Sell
109,087
-3,569
-3% -$13.4K ﹤0.01% 3843
2022
Q3 		$514K Buy
112,656
+140
+0.1% +$1.39K ﹤0.01% 3709
2022
Q2 		$2.97M Buy
112,516
+4,924
+5% +$174K ﹤0.01% 2970
2022
Q1 		$4M Buy
107,592
+5,170
+5% +$225K ﹤0.01% 2930
2021
Q4 		$5.99M Sell
102,422
-196
-0.2% -$12.8K ﹤0.01% 2794
2021
Q3 		$8.44M Buy
102,618
+2,178
+2% +$189K ﹤0.01% 2587
2021
Q2 		$9.49M Buy
100,440
+65,879
+191% +$4.88M ﹤0.01% 2493
2021
Q1 		$2.21M Buy
34,561
+24,960
+260% +$1.67M ﹤0.01% 3212
2020
Q4 		$558K Buy
9,601
+1,212
+14% +$30.9K ﹤0.01% 3555
2020
Q3 		$175K Hold
8,389
– – ﹤0.01% 3753
2020
Q2 		$132K Hold
8,389
– – ﹤0.01% 3786
2020
Q1 		$110K Buy
8,389
+69
+0.8% +$1.26K ﹤0.01% 3735
2019
Q4 		$172K Buy
8,320
+2,692
+48% +$68K ﹤0.01% 3844
2019
Q3 		$180K Hold
5,628
– – ﹤0.01% 3807
2019
Q2 		$122K Buy
5,628
+479
+9% +$12.7K ﹤0.01% 3914
2019
Q1 		$197K Hold
5,149
– – ﹤0.01% 3749
2018
Q4 		$231K Buy
5,149
+591
+13% +$32.2K ﹤0.01% 3628
2018
Q3 		$198K Hold
4,558
– – ﹤0.01% 3770
2018
Q2 		$187K Buy
4,558
+3,555
+354% +$124K ﹤0.01% 3735
2018
Q1 		$27K Hold
1,003
– – ﹤0.01% 4001
2017
Q4 		$33K Hold
1,003
– – ﹤0.01% 3965
2017
Q3 		$48K Hold
1,003
– – ﹤0.01% 3942
2017
Q2 		$56K Hold
1,003
– – ﹤0.01% 3934
2017
Q1 		$58K Hold
1,003
– – ﹤0.01% 3925
2016
Q4 		$112K Hold
1,003
– – ﹤0.01% 3770
2016
Q3 		$125K Buy
+1,003
New +$109K ﹤0.01% 3749

Other funds holding VTGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
LM
Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return

Geode Capital Management's VTGN Position: Q1 2026 in Review

Geode Capital Management increased its VistaGen Therapeutics (VTGN) stake by 28% in Q1 2026, buying an estimated $61.1K and bringing the position to 453,391 shares worth $259K. The position accounts for ﹤0.01% of the portfolio, ranked #3838.

Geode Capital Management first reported a position in VTGN in Q3 2016 and has held it in 39 quarters since. The position peaked at $9.49M in Q2 2021. 56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.

  • Geode Capital Management held 453,391 shares of VistaGen Therapeutics worth $259K as of Q1 2026.
  • Geode Capital Management bought 100,555 VistaGen Therapeutics shares in Q1 2026, an estimated $61.1K.
  • VistaGen Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3838 holding.
  • Geode Capital Management first reported a position in VistaGen Therapeutics in Q3 2016 and has held it in 39 quarters since.
  • Geode Capital Management's VistaGen Therapeutics position peaked at $9.49M in Q2 2021.
  • 56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.